Outpace Bio vs Saluda Medical

Side-by-side comparison of AI visibility scores, market position, and capabilities

Saluda Medical leads in AI visibility (74 vs 36)
Outpace Bio logo

Outpace Bio

EmergingLife Sciences & BioTech

AI-Driven Cell Therapy for Solid Tumors

Outpace Bio is a clinical-stage biotech using AI-powered protein design and synthetic biology to develop next-generation cell therapies targeting solid tumors; founded by pioneers in CAR-T and protein engineering; raised $109M Series B in 2024;

AI VisibilityBeta
Overall Score
D36
Category Rank
#93 of 198
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
37
Gemini
31

About

Outpace Bio is a clinical-stage biotechnology company headquartered in Seattle, Washington, founded to address one of the most significant unmet needs in oncology: creating effective cell therapies for solid tumors. While CAR-T cell therapies have transformed treatment of blood cancers, they have largely failed against solid tumors due to the immunosuppressive tumor microenvironment, T-cell exhaustion, and tumor heterogeneity. Outpace Bio applies AI-powered protein design and synthetic biology to engineer novel cellular logic circuits — custom genetic programs embedded in therapeutic T cells — that allow the cells to sense the tumor environment and respond adaptively rather than becoming exhausted or suppressed.

Full profile
Saluda Medical logo

Saluda Medical

LeaderLife Sciences & BioTech

Neuromodulation & Spinal Cord Stimulation

Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.

AI VisibilityBeta
Overall Score
B74
Category Rank
#10 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
68
Gemini
80

About

Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#93
Category Rank
#10
79
AI Consensus
73
stable
Trend
stable
35
ChatGPT
72
37
Perplexity
68
31
Gemini
80
40
Claude
71
33
Grok
71

Key Details

Category
AI-Driven Cell Therapy for Solid Tumors
Neuromodulation & Spinal Cord Stimulation
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.